Sam Gandy-Michelle Ehrlich Labs at Mount Sinai Health System in NYC
The Gandy-Ehrlich Labs use NIH-AMP-AD funded iterative "Big Data" paradigms to make and validate major networks underlying neurodegenerative diseases leading to reports in the highest impact journals (Neuron, PLoS Genetics, Molecular Psychiatry, Acta Neuropathologica, N Eng J Med, Nature Revs Neurology).
Microglial Network Mechanisms in Tauopathy
Audrain M, et al. Deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Molecular Psychiatry. 2018 doi: 10.1038/s41380-018-0258-3.
HHV6a/7 in Dementia Progression
Readhead B, et al Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human HV6a/7. Neuron. 2018, doi: 10.1016/ j.neuron.2018.05.023 (Most press impressions among 8,000+ papers in Neuron to date).
iPSC/Neurogenesis Treatment of Dementia, Dystonia, PTSD including human clinical trials
Zakirova Z, et al. Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways & functions. PLoS Genetics. 2018. doi:10.1371/journal.pgen.1007169. Ortiz-Virumbrales M, et al. CRISPR/Cas9-Correctable mutation related molecular and physiological phenotypes in iPSC- derived Alzheimer'sPSEN2 (N141I) neurons. Acta Neuropathol Commun. doi: 10.1186/s40478-017-0475-z. and Perez-Garcia G, et al PTSD-related behavioral traits in a rat model of blast-induced mTBI are reversed by the mGluR2/3 receptor antagonist BCI-838. eNeuro 2018. doi:10.1523/ENEURO.0357-17.2018.
Animal handling, cell culture, and basic immunomethods and/or electrophysiology strongly preferred. Human clinical biomarker and/or neuropsychological expertise occasionally required for some projects.